IMAC (BACK) Competitors $0.06 -0.03 (-35.03%) As of 07/21/2025 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock BACK vs. BTTX, UPHL, ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, TALKW, and TOIIWShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), Talkspace (TALKW), and Oncology Institute (TOIIW). These companies are all part of the "healthcare" industry. IMAC vs. Its Competitors Better Therapeutics UpHealth Aclarion American Oncology Network Digital Health Acquisition LifeMD Ontrak P3 Health Partners Talkspace Oncology Institute Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment. Which has preferable valuation & earnings, BTTX or BACK? IMAC has higher revenue and earnings than Better Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBetter TherapeuticsN/AN/A-$39.76MN/AN/AIMAC$72.05K1.73-$9.42MN/AN/A Does the media prefer BTTX or BACK? In the previous week, IMAC had 7 more articles in the media than Better Therapeutics. MarketBeat recorded 7 mentions for IMAC and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat IMAC's score of -0.03 indicating that Better Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Better Therapeutics Neutral IMAC Neutral Is BTTX or BACK more profitable? Company Net Margins Return on Equity Return on Assets Better TherapeuticsN/A N/A N/A IMAC N/A N/A -325.44% Do institutionals and insiders have more ownership in BTTX or BACK? 34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 5.8% of IMAC shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by company insiders. Comparatively, 12.3% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, BTTX or BACK? Better Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, IMAC has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. SummaryBetter Therapeutics and IMAC tied by winning 4 of the 8 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BACK vs. The Competition Export to ExcelMetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$125K$125K$5.52B$9.40BDividend YieldN/AN/A4.00%4.03%P/E RatioN/AN/A27.4419.21Price / Sales1.731.73441.7498.81Price / CashN/AN/A24.9928.17Price / Book-0.09N/A8.235.70Net Income-$9.42M-$9.42M$3.24B$257.84M7 Day PerformanceN/AN/A2.56%2.96%1 Month PerformanceN/AN/A8.35%13.26%1 Year PerformanceN/AN/A33.89%17.12% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BACKIMACN/A$0.06-35.0%N/A-96.0%$125K$72.05K0.00180Gap DownBTTXBetter TherapeuticsN/A$0.00flatN/AN/A$5KN/A0.0040UPHLUpHealthN/A$0.00flatN/A-100.0%$4K$130M0.001,750ACONWAclarionN/A$0.02+4.1%N/A+5.6%$0.00$54.60K0.007News CoveragePositive NewsGap UpAONCAmerican Oncology NetworkN/A$10.00+1.0%N/A+708.8%$0.00$1.34B0.001,520Gap DownDHACWDigital Health AcquisitionN/A$0.04flatN/A-73.1%$0.00N/A0.00N/AGap UpLFMDPLifeMDN/A$23.15-0.3%N/A+6.4%$0.00$234.01M0.00230Positive NewsOTRKPOntrakN/A$0.26+13.3%N/A+23.1%$0.00$10.84M0.00250Gap DownPIIIWP3 Health PartnersN/A$0.01+20.5%N/AN/A$0.00$1.49B0.00500Positive NewsGap DownTALKWTalkspaceN/A$0.08+15.1%N/A-33.4%$0.00$194.36M0.00500Positive NewsGap DownTOIIWOncology InstituteN/A$0.09-1.0%N/A+255.0%$0.00$403.15M0.00660 Related Companies and Tools Related Companies Better Therapeutics Competitors UpHealth Competitors Aclarion Competitors American Oncology Network Competitors Digital Health Acquisition Competitors LifeMD Competitors Ontrak Competitors P3 Health Partners Competitors Talkspace Competitors Oncology Institute Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BACK) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BACK Stock Alerts